主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
COCP
#3808
Cocrystal Pharma, Inc. Common Stock
1.0
4
-2.80%
版块:
基础:
利润货币:
日范围
年范围
日变化
-2.80%
每月变动
0.00%
6个月变化
-31.58%
年变化
-40.23%
前一天收盘价
1.0
7
Open
1.0
2
Bid
Ask
Low
1.0
2
High
1.0
4
交易量
7
市场
股票
医疗保健
COCP
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Cash from operating activities
-21.53 M
3.17 M
-2.94 M
-2.15 M
-1.36 M
-3.28 M
Cash from investing activities
0
0
0
0
12 K
12 K
Cash from financing activities
0
0
—
—
0
—
Free cash flow
-21.53 M
3.17 M
-2.94 M
-2.15 M
-1.37 M
-3.29 M
新闻
Cocrystal Pharma advances norovirus drug candidate to Phase 1b trial
Tuesday’s Insider Activity: Major Buys at CBC, COCP; Sells at ARES, RKLB
菲利普·弗罗斯特购入价值18,812美元的Cocrystal Pharma (COCP)股票
Phillip Frost buys Cocrystal Pharma (COCP) shares worth $18,812
Cocrystal Pharma raises $1.03 million in private placement from directors
Cocrystal Pharma receives $500,000 NIH grant for influenza drug
Cocrystal Pharma完成470万美元的注册直接发行
Cocrystal Pharma closes $4.7 million registered direct offering
Cocrystal Pharma通过定向增发筹集470万美元资金
Cocrystal Pharma raises $4.7 million in registered direct offering
Cocrystal的诺如病毒药物CDI-988进入1b期研究
Cocrystal’s norovirus drug CDI-988 advances to phase 1b study